Cardiotoxicity in a Patient with Multiple Relapses of Non-Hodgkin Lymphoma.

Q4 Medicine
West African journal of medicine Pub Date : 2024-12-30
J Alburqueque-Melgarejo, L J Valverde-Graciano, J C Roque-Quezada, H M Virú-Flores, B Beltrán-Gárate, L Villela
{"title":"Cardiotoxicity in a Patient with Multiple Relapses of Non-Hodgkin Lymphoma.","authors":"J Alburqueque-Melgarejo, L J Valverde-Graciano, J C Roque-Quezada, H M Virú-Flores, B Beltrán-Gárate, L Villela","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced cardiomyopathy is one of the most important adverse effects in cancer treatment. Many chemotherapeutic agents are known to be cardiotoxic, including anthracyclines, monoclonal antibodies, alkylating agents, and protein kinase inhibitors.</p><p><strong>Objective: </strong>It is intended to indicate a mechanism of multiple cardiac injury after exposure to various chemotherapeutic agents with cardiotoxic potential. This article illustrates the case of a 70-year-old male patient diagnosed with non-Hodgkin's lymphoma with multiple relapses and malignant transformation to diffuse large B-cell lymphoma who received multiple cycles of chemotherapy with periods of complete remission, who presented to the hospital emergency with decompensated reduced ejection fraction heart failure (EF:40%).</p><p><strong>Results: </strong>During the hospitalization the patient suffered refractory electrolyte imbalances and hospital-acquired infections. Although the patient received hypertonic saline solution, multiple potassium challenges, and extended spectrum antibiotics, the patient passed away.</p><p><strong>Conclusion: </strong>Exposure to different chemotherapeutic agents with cardiotoxic potential included in non-Hodgkin lymphoma treatment schemes can trigger myocardial injury by different mechanisms. Cardiooncology is a field that is emerging and working on new strategies for the diagnosis, prevention, and management of chemotherapy-induced cardiotoxicity.</p>","PeriodicalId":23680,"journal":{"name":"West African journal of medicine","volume":"41 12","pages":"1225-1230"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"West African journal of medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chemotherapy-induced cardiomyopathy is one of the most important adverse effects in cancer treatment. Many chemotherapeutic agents are known to be cardiotoxic, including anthracyclines, monoclonal antibodies, alkylating agents, and protein kinase inhibitors.

Objective: It is intended to indicate a mechanism of multiple cardiac injury after exposure to various chemotherapeutic agents with cardiotoxic potential. This article illustrates the case of a 70-year-old male patient diagnosed with non-Hodgkin's lymphoma with multiple relapses and malignant transformation to diffuse large B-cell lymphoma who received multiple cycles of chemotherapy with periods of complete remission, who presented to the hospital emergency with decompensated reduced ejection fraction heart failure (EF:40%).

Results: During the hospitalization the patient suffered refractory electrolyte imbalances and hospital-acquired infections. Although the patient received hypertonic saline solution, multiple potassium challenges, and extended spectrum antibiotics, the patient passed away.

Conclusion: Exposure to different chemotherapeutic agents with cardiotoxic potential included in non-Hodgkin lymphoma treatment schemes can trigger myocardial injury by different mechanisms. Cardiooncology is a field that is emerging and working on new strategies for the diagnosis, prevention, and management of chemotherapy-induced cardiotoxicity.

非霍奇金淋巴瘤多次复发患者的心脏毒性。
背景:化疗引起的心肌病是癌症治疗中最重要的不良反应之一。已知许多化疗药物具有心脏毒性,包括蒽环类药物、单克隆抗体、烷基化剂和蛋白激酶抑制剂。目的:旨在揭示暴露于具有心脏毒性的各种化疗药物后多处心脏损伤的机制。本文描述了一位70岁男性患者,诊断为非霍奇金淋巴瘤,多次复发并恶性转化为弥漫性大b细胞淋巴瘤,他接受了多个周期的化疗,并有完全缓解期,他以失代偿性射血分数降低心力衰竭(EF:40%)就诊于医院急诊。结果:患者住院期间出现难治性电解质失衡和院内获得性感染。尽管患者接受了高渗生理盐水、多次钾挑战和广谱抗生素治疗,但患者仍然死亡。结论:暴露于非霍奇金淋巴瘤治疗方案中不同的具有心脏毒性的化疗药物可通过不同的机制引发心肌损伤。心脏肿瘤学是一个新兴的领域,致力于化疗引起的心脏毒性的诊断、预防和管理的新策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
West African journal of medicine
West African journal of medicine Medicine-Medicine (all)
自引率
0.00%
发文量
212
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信